Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted‐Synthetic Disease‐Modifying Antirheumatic Drugs
Main finding · Serious infections, TNFi initiatorsResult — go to the resultAdjusted hazard ratio 1.5 95% CI 1.2–1.9Authors' conclusion
Frailty is an important predictor for the risk of adverse outcomes among patients with RA treated with biologic or targeted-synthetic DMARDs.
Study context
- Population
- Patients with rheumatoid arthritis (RA) <65 years old, new users of tumor necrosis factor inhibitors (TNFi), non-TNFi bDMARDs or Janus kinase inhibitors (JAKi), MarketScan 2008–2019; mean (±SD) age 48.1 ± 10.1
- Participants
- 57,980 patients
- Exposure
- Frail vs nonfrail patients with RA initiating b/tsDMARDs
- Frailn = 3,560
- Outcome
- Time to serious infection
Methodological detailsclaims-based (MarketScan), new-user design, Cox proportional hazards
- Claims-based (MarketScan)
- New-user design
- Cox proportional hazards
Main finding
Serious infections, TNFi initiators
Adjusted hazard ratio
1.5
95% CI 1.2–1.9
Frailvs Nonfrail
aHR 1.5 (95% CI 1.2–1.9)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Inpatient admissions, TNFi initiators | 1.4 (1.3–1.6) | |
| Any infection, by drug classFrailvs NonfrailTNFi | 1.2 (1.1–1.3) | |
| Any infection, by drug classFrailvs Nonfrailnon-TNFi | 1.2 (1.0–1.4) | |
| Any infection, by drug classFrailvs NonfrailJAKi | 1.4 (1.0–2.0) | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted‐Synthetic Disease‐Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken). Published 4 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →